



Business

ProteoTech Receives Issuance of US Patent Pertaining To the Generation of Proteoglycan Transgenic Mice



PROTEOTECH LOGO

ProteoTech Inc. logo. (PRNewsFoto)[AS]
 KIRKLAND, WA USA 02/20/2002

KIRKLAND, Wash., May 27 /PRNewswire/ -- ProteoTech (Proteoglycan Technologies) Inc. was recently issued a US patent pertaining to the generation of new transgenic animals that overproduce a particular proteoglycan involved in Alzheimer's disease and other amyloid disorders.

(Logo: <http://www.newscom.com/cgi-bin/prnh/20020220/SFW009LOGO>)

On May 13, 2003, ProteoTech was issued US Patent No. 6,563,016 B1 entitled "Perlecan Transgenic Animals and Methods of Identifying Compounds for the Treatment of Amyloidoses." The patent is assigned to University of Washington and licensed exclusively to ProteoTech. The patent invented by Alan D. Snow (now ProteoTech President & CSO), Ken-ichiro Fukuchi, and John Hassell, relate to the generation of novel genetically engineered mice that overproduce a particular heparan sulfate proteoglycan that has been implicated to play an important role in a variety of human diseases, including Alzheimer's and other amyloid disorders. These transgenic mice will be useful for further identifying the important role that specific heparan sulfate proteoglycans play in a variety of human diseases including Alzheimer's, Parkinson's, type 2 diabetes, systemic amyloidosis, prion diseases, and other amyloid disorders.

Alan D. Snow, Ph.D., President & CSO of ProteoTech was also a featured speaker at the 6th International Conference on Alzheimer's disease and Parkinson's disease in Seville, Spain during this last month. Dr. Snow's seminar entitled "Specific Proteoglycans/Glycosaminoglycans in the Pathogenesis of Alzheimer's Disease and Related Disorders" highlighted significant scientific breakthroughs by ProteoTech scientists involving the important role of proteoglycans in Alzheimer's disease and other amyloid disorders. ProteoTech scientists have re-created the world's first Alzheimer's amyloid plaques in a test-tube and have developed novel methods to screen for and identify new Alzheimer's disease therapeutics. Amyloid plaque formation occurs in the brains of all patients with Alzheimer's disease and is believed to play an important role in memory loss and dysfunction.

ProteoTech is a private drug discovery and research development Company focused on therapeutics and diagnostics for specific human diseases that involve "proteoglycans" in the disease pathogenesis. Proteoglycans are produced by virtually all cell of the human body and play significant roles in the pathogenesis of a number of human diseases. ProteoTech is in pre-clinical development and has identified novel compounds for the treatment of Alzheimer's disease, Parkinson's disease, type 2 diabetes and systemic amyloidosis. ProteoTech is a leader in the field of proteoglycan and amyloid disease research and development, and owns an impressive and growing intellectual property estate. ProteoTech is currently raising additional equity funding via a private placement and sale of Preferred Series B stock.

News Headlines from:



PR Newswire

United Business Media

Search nbc6.com



NEED A CAR?



"I don't have
any time."

[Contact Us](#)[Terms](#)[Privacy](#)[Advertising](#)[Site Map](#)[About Us](#)

© Belo Interactive, Inc.